Using the WHO model list of essential medicines to update a national essential medicines list
Since 1977, WHO has been working with countries to design the package of essential medicines as an integral component of treatment within the continuum of care, developing and disseminating the Model List ...of Essential Medicines (Model List). WHO is committed to supporting Member States in sharing best practices in selecting
essential medicines, and in developing processes for the selection of medicines for national essential medicines lists (national EMLs, or NEMLs) consistent with the evidence-based methods used for updating the WHO Model List.
more
В настоящем докладе освещены текущие и вновь появляющиеся проблемы, связанные с воздействием табака на здоровье детей в Регионе, а также рассмотрены нормативно-пр...авовые механизмы, обязательства и другие инструменты, которые государства-члены должны использовать для защиты детей от табака. Сюда включены и новые подходы, которые можно и нужно применять, для того чтобы Европейский регион стал свободным от табака.
more
Health Situation
Health policies and systems
Cooperation for Health
WHO Country Cooperation Strategic Agenda (2008-2013)
Towards the Elimination of Mother-to-Child Transmission of HIV and keeping mothers Alive. 2012-2015
The WHO Vision and eye screening implementation handbook (VESIH) offers a step-by-step guidance for conducting vision and eye screenings in community and primary care settings. The evidence-based interventions are drawn from the WHO Package of eye care interventions and developed with a focus on del...ivering screenings easily, safely, and effectively in low- and low–intermediate-resource settings. The early identification through screenings ensures timely treatments and management to avoid vision impairment in high-risk populations, including newborns, pre-school children, school children, and older adults.
more
From raising awareness to building capacity
Meeting Report
World Health Organization, Geneva, Switzerland 16 -18 September 2013
Community Health Volunteers
This Implementation Kit (I-Kit), developed by the Health Communication Capacity Collaborative (HC3), which is funded by USAID and based at the Johns Hopkins Center for Communication Programs, offers structured guidance for improving social and behavioural change communication (SBCC) strategies relat...ed to malaria in pregnancy (MiP). Designed for programme managers and stakeholders, the toolkit addresses critical communication gaps in MiP programming, particularly among service providers. It provides tools to help users integrate MiP into situation analyses, segment audiences, define behavioural objectives and draft strategic communication plans.
MiP poses a significant public health challenge, contributing to maternal and neonatal mortality and morbidity in sub-Saharan Africa. Although effective interventions exist, such as the use of insecticide-treated nets, intermittent preventive treatment in pregnancy (IPTp) and timely diagnosis and treatment, their implementation remains inconsistent. The I-Kit supports more effective SBCC planning and implementation, with the aim of increasing the uptake and impact of these interventions and ultimately reducing malaria-related deaths and illness among pregnant women and newborns.
more
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more